Trevi Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2018 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Trevi Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q4 2024.
  • Trevi Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$12.2M, a 37% decline year-over-year.
  • Trevi Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$51.5M, a 51.9% decline year-over-year.
  • Trevi Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$51.5M, a 51.9% decline from 2023.
  • Trevi Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$33.9M, a 13.4% decline from 2022.
  • Trevi Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$29.9M, a 7.91% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$51.5M -$12.2M -$3.31M -37% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-18
Q3 2024 -$48.2M -$14.1M -$5.04M -55.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$43.2M -$13.3M -$4.91M -58.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$38.3M -$11.9M -$4.34M -57.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$33.9M -$8.93M -$2.28M -34.2% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-18
Q3 2023 -$31.6M -$9.05M -$640K -7.62% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$31M -$8.38M -$562K -7.19% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$30.4M -$7.56M -$538K -7.66% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$29.9M -$6.66M +$1.62M +19.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-20
Q3 2022 -$31.5M -$8.41M -$1.46M -21% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$30.1M -$7.82M +$1.35M +14.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$31.4M -$7.03M +$1.06M +13.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$32.5M -$8.27M +$920K +10% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 -$33.4M -$6.95M +$297K +4.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$33.7M -$9.17M -$1.75M -23.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$31.9M -$8.09M +$550K +6.37% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$32.5M -$9.19M -$2.43M -35.9% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-17
Q3 2020 -$30.1M -$7.24M +$406K +5.31% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$30.5M -$7.41M +$4K +0.05% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$30.5M -$8.64M -$3.83M -79.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$26.6M -$6.77M -$837K -14.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 -$25.8M -$7.65M -$2.69M -54.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$23.1M -$7.42M -$3.04M -69.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$20.1M -$4.81M -$1.67M -53.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$18.4M -$5.93M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-16
Q3 2018 -$4.96M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$4.38M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-12
Q1 2018 -$3.14M Jan 1, 2018 Mar 31, 2018 10-Q 2019-06-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.